Capital Increase / Dilution2026-07-22

Amendment: Decision on CB Issuance

LCB

리가켐바이오

141080

-0.50

Signal Score

50CNeutral
Score50 / 100

Historical Avg Return (5d)

+0.00%

Data Coverage

100%n=2589

Risk-adjusted indicator based on 2589 historical DART filings. For informational purposes only — not investment advice.

Financial Impact

NEGATIVE

Key Numbers

  • • Event: Decision on Issuance of Convertible Bonds (Amendment)

AI Analysis Summary

LigaChem Biosciences Inc. has filed an amendment to a Material Fact Report regarding a decision to issue convertible bonds. This indicates a potential future dilution for existing shareholders, as convertible bonds can be converted into new shares, increasing the total outstanding shares. The specific terms, such as issuance amount, conversion price, and number of shares, are not available in this title-only analysis, but the issuance of convertible bonds generally carries a negative financial impact due to the potential for dilution.

How This Event Is Evaluated

Capital Raise Evaluation

Capital raise events are evaluated by estimating dilution pressure, funding purpose, pricing terms, and impact on existing shareholders.

AI is used to interpret disclosures and extract structured data.

Signal scores are generated using event-specific methodologies and quantitative models.

  • Potential dilution rate
  • Issuance or conversion price
  • Funding purpose
  • Shareholder value impact
Read our full scoring methodology →

This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.

AI-processed analysis. Based on: [기재정정]주요사항보고서(전환사채권발행결정). Source: Financial Supervisory Service (금융감독원 전자공시시스템). Raw government data is not redistributed. Not investment advice.